HOPKINTON, Mass., Oct. 25, 2016 /PRNewswire/ -- Arteriocyte, Inc., a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, presented new updates on its development of an advanced wound dressing as a part of the Acute Care Cover for Severely Injured Limbs (ACCSIL) program, a unique program created by the Office of Naval Research (ONR).
ACCSIL is expected to be an advanced field dressing with capabilities beyond those currently available today for battlefield care of severely injured arms or legs. It is intended for application by corpsmen/medics/first responders at the point of injury and removal by medical care providers at Medical Treatment Facilities (MTF) that can provide definitive care. This product will preserve viable tissue and diminish post-injury, negative, secondary sequelae to reduce morbidity and mortality. ACCSIL is intended to preserve the tissues of the injured limb in the best possible state during delays before evacuation and during evacuation itself. Optimally, at the time ACCSIL is removed, the limb, although injured, will be as fresh, well perfused, viable, and uninfected as at the moment of injury. The final product will consist of two independent components: a) an internal bioactive coating composed of several pharmacological interventions to mitigate progressive injury and aid in preserving tissue, limb, and systemic health, and b) a conformal cover to serve as a physical barrier to contain/protect the remaining tissue.
As part of this project, Arteriocyte has been tasked and funded for the development, optimization, and pre-clinical evaluation of a proprietary bandage that is formulated to deliver growth factors, antimicrobial and hemostatic agents in optimal concentrations to help maintain tissue viability in severely injured limbs. The finished product is expected to be shelf stable at room temperature, easy to apply in the battlefield, and easy to integrate with other components of the ACCSIL bandage currently in development by other research organizations.
A prototype of the trauma dressing has already been completed, and the company expects to finish in-vitro optimization studies, and pre-clinical safety-toxicity and efficacy studies as per ISO and ASTM standards and guidelines before the end of the year. Future optimization of the growth factor dressing will allow for a next generation product that will co-deliver antimicrobial components and clotting agents in addition to a sustained release of growth factors for maintaining tissue viability. Arteriocyte will collaborate with the ACCSIL team to integrate all components into a final product. The status of the development efforts was presented at the Annual Review meeting conducted by ONR in July 2016, and at the Military Health System Research Symposium (MHSRS) in August 2016.
"The ACCSIL project represents another advance towards creating novel technologies to improve treatment for our battlefield injured. We are honored to be invited by ONR to help create the first advanced wound dressing that co-delivers growth factors, antimicrobial and hemostatic agents to improve tissue viability and speed wound healing," said Arteriocyte CEO, Don Brown.
Arteriocyte, a leading clinical stage biotechnology company, is dedicated to developing novel cellular products and medical devices to help patients heal faster. Arteriocyte leverages its expertise in stem cell and tissue engineering to develop a broad portfolio of cell based therapeutics to improve patient outcomes.
For Inquiries about ACCSIL or product development questions: Caitlin Smith (216)456-9654, email@example.com
SOURCE Arteriocyte, Inc.